Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

Neuroscience Research

Volumn 47, Issue 2, 2003, Pages 201-207

  Gilgun Sherki, Yossi ^a   Panet, Hana ^a   Holdengreber, Vered ^a   Mosberg Galili, Ronit ^a   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Axonal damage; Experimental autoimmune encephalomyelitis (EAE); Glatiramer acetate; Multiple sclerosis (MS); Myelin oligodendrocyte glycoprotein (MOG)

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIBODY; GLATIRAMER; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFILAMENT PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIGHT DARK CYCLE; MOUSE; NERVE FIBER; NEUROFILAMENT; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SILVER STAINING; STATISTICAL ANALYSIS;

EID: 0141516543     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-0102(03)00217-7     Document Type: Article

References (42)

1. Aharoni R., Teitelbaum D., Sela M., et al. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J. Neuroimmunol. 91:1998;135-146.
2. Angelov D.N., Waibel S., Guantinas-Lichius O., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for aprocmyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 100:2003;4790-4795.
3. Ben-Nun A., Mendel I., Bakimer R., et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 243:1996;S14-S22.
4. Charcot M. Histologie de la sclerose en plaque. Gaz. Hosp. 41:1868;554-556.
5. De Stefano N., Narayanan S., Matthews P.M., et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain. 122:1999;1933-1939.
6. Ferguson B., Matyszak M.K., Esivi M.M. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;292-299.
7. Filippi M., Rovaris M., Rocca M.A., et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology. 57:2001;731-733.
8. Fridkis-Hareli M., Teitelbaum D., Gurevich E., et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells: specificity and promiscuity. Proc. Natl. Acad. Sci. 91:1994;4872-4876.
9. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapses rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
10. Johnson K.P., Brooks B.R., Cohen J.A., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 50:1998;701-708.
11. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurol. Suppl. 5:2001;S16-S24.
12. Kerlero de Rosbo N., Mendel I., Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur. J. Immunol. 25:1995;985-993.
13. Kipnis J., Yoles E., Porat Z., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. USA. 97:2000;7446-7451.
14. Kornek B., Storch M.K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157:2000;267-276.
15. Lassmann H., Wekerle H. Experimental models of multiple sclerosis. Compston A., Ebers G., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis. 1998;409-433 Churchill Livingstone, London, Edinburgh, New York.
16. Li Q.Q., Burt D.R., Bever T. Glatiramer acetate inhibition of tumor necrosis factor α-induced RANTES expression and release from U-251 MG human astrocytic cells. J. Neurochem. 77:2001;1208-1217.
17. Luna L.G. Luna L.G. Manual of Histologic Staining Methods of Armed Forces Institute of Pathology. third ed:1968;193-194 McGraw-Hill, Inc.
18. Luna L.G. Luna L.G. Manual of Histologic Staining Methods of Armed Forces Institute of Pathology. third ed:1968;203-204 McGraw-Hill, Inc.
19. Mancardi G., Hart B., Roccatagliata L., et al. Demyelination and axonal damage in non-humans primate model of multiple sclerosis. J. Neurol. Sci. 184:2001;41-49.
20. Matthews P.M., De Stefano N., Narayanan S., et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 18:1998;327-336.
21. Mendel I., Katz A., Kozak N., et al. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28:1998;1727-1737.
22. Neuhaus O., Farina C., Wekerl H., et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 56:2001;702-708.
23. Noseworthy J.H., Lucchinetti C., Rodriguez M., et al. Multiple sclerosis. New Engl. J. Med. 343:2000;938-992.
24. Offen D., Kaye J.F., Bernard O., et al. Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG) -induced experimental autoimmune encephalomyelitis (EAE). J. Mol. Neurosci. 15:2000;167-176.
25. Pike G.B., De Stefano N., Narayanan S., et al. Combined magnetization transfer and proton spectroscopy imaging in the assessment of pathologic brain lesions in multiple sclerosis. Am. J. Neuroradiol. 20:1999;829-837.
26. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:2000;67-70.
27. Racke M.K., Martin R., McFarland H., et al. Copolymer 1 induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J. Neuroimmunol. 37:1992;75-84.
28. Raine C.S., Cross A.H. Axonal dystrophy as a consequence of long-term demyelination. Lab. Invest. 60:1989;714-725.
29. Rieckmann P., Mauser M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr. Opin. Neurol. 15:2002;361-370.
30. Schori H., Kipnis J., Yoles E., et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. USA. 98:2001;3398-3403.
31. Silber E., Sharief M.K. Axonal degeneration in the pathogenesis of multiple sclerosis. J. Neurol. Sci. 170:1999;11-18.
32. Smith T., Groom A., Zhu B., et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6:2000;62-66.
33. Stinissen P., Raus J., Zhang J. Autoimmune pathogenesis of multiple sclerosis: Role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17:1997;33-75.
34. Teitelbaum D., Aharoni R.M., Arnon R., et al. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer 1 Cop 1. Proc. Natl. Acad. Sci. 85:1988;9724-9728.
35. Teitelbaum D., Milo R., Arnon R., et al. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. 89:1992;137-141.
36. Teitelbaum D., Fridkis-Hareli M., Arnon R., et al. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:1996;209-217.
37. Teitelbaum D., Sela M., Arnon R. Copolymer 1 from the laboratory to FDA. Isr. J. Med. Sci. 33:1997;280-284.
38. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. New Engl. J. Med. 338:1998;278-285.
39. Trapp B.D., Ransohoff R., Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12:1999;295-302.
40. Weiner H. COP 1 therapy for multiple sclerosis. New Engl. J. Med. 317:1987;442-444.
41. Werner P., Pitt D., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocytes and axonal damage. Ann. Neurol. 50:2001;169-180.
42. Ziemssen T., Kumpfel T., Klinkert W.E., et al. Glatiramer acetate-specific T-helper 1 and 2-type cell lines produce brain derived neurotrophic factor (BDNF): implications for multiple sclerosis therapy. Brain. 125:2002;2381-2391.